Sirna Therapeutics, Inc.

Ribozyme Pharmaceuticals, Incorporated

Mark Reynolds

Leonid Beigelman

Jasenka Matulic-Adamic

Peter Haeberli

Alexander Karpeisky

David Sweedler

Nilabh Chaudhary

John Min

James A McSwiggen

Tod M Woolf

Thale Jarvis

James D Thompson

Alex Karpeisky

Laurent Bellon

Michael Zwick

This invention features permeability enhancer molecules, and methods, to increase membrane permeability of various molecules, such as nucleic acids, polynucleotides, oligonucleotides, enzymatic nucleic acid molecules, antisense nucleic acid molecules, 2-5A antisense chimeras, triplex forming oligonucleotides, decoy RNAS, dsRNAs, siRNAs, aptamers, or antisense nucleic acids containing nucleic acid cleaving chemical groups, peptides, polypeptides, proteins, carbohydrates, steroids, metals and small molecules, thereby facilitating cellular uptake of such molecules.

Compositions for the delivery of negatively charged molecules

This invention relates to novel chemically-modified nucleic acid molecules having specific formulae that exhibit increased resistance to nucleases and increased binding affinity to target nucleic acid molecules. The invention further relates to methods of modulating gene expression using the novel chemically modified nucleic acid molecules, and compositions and cells comprising said molecules.

Nucleic acid molecules with novel chemical compositions capable of modulating gene expression

This invention features permeability enhancer molecules, and methods, to increase membrane permeability of negatively charged polymers thereby facilitating cellular uptake of such polymers.

Growing community of inventors

Pleasanton, CA, United States of America

Mark Reynolds